Clinical trial
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy: To Assess How the 670G System Adapts to the Introduction of Fiasp® Insulin
NCT03554486 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy: To Assess How the 670G System Adapts to the Introduction of Fiasp® Insulin
- Lead sponsor
- Stanford University
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 23, 2018
- Completion date
- March 30, 2019
- Enrollment
- 27 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.